Molecular Partners AG (MLLCF)
OTCMKTS · Delayed Price · Currency is USD
2.250
-0.100 (-4.26%)
At close: Jan 28, 2026
Molecular Partners AG Revenue
In the year 2024, Molecular Partners AG had annual revenue of 4.97M CHF, down -29.38%.
Revenue
4.97M CHF
Revenue Growth
-29.38%
P/S Ratio
n/a
Revenue / Employee
32.48K CHF
Employees
153
Market Cap
170.90M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
| Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
| Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
| Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
| Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
| Dec 31, 2019 | 20.38M | 10.03M | 96.84% |
| Dec 31, 2018 | 10.36M | -9.66M | -48.27% |
| Dec 31, 2017 | 20.02M | -3.02M | -13.13% |
| Dec 31, 2016 | 23.04M | -6.08M | -20.88% |
| Dec 31, 2015 | 29.12M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
Molecular Partners AG News
- 23 days ago - Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 27 days ago - Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting - GlobeNewsWire
- 3 months ago - Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program Transcript - Seeking Alpha
- 3 months ago - Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action - GlobeNewsWire
- 3 months ago - Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 - GlobeNewsWire
- 3 months ago - Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting - GlobeNewsWire